Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $40.19 and traded as high as $48.00. Global X Genomics & Biotechnology ETF shares last traded at $47.83, with a volume of 10,635 shares.

Global X Genomics & Biotechnology ETF Price Performance

The firm has a fifty day simple moving average of $45.40 and a two-hundred day simple moving average of $40.19. The firm has a market capitalization of $54.05 million, a P/E ratio of -20.44 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, January 7th. Stockholders of record on Tuesday, December 30th will be paid a dividend of $0.5912 per share. The ex-dividend date is Tuesday, December 30th. This represents a dividend yield of 259.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio is presently -26.50%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its position in Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after purchasing an additional 489 shares during the period. Halbert Hargrove Global Advisors LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 182.4% in the second quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock valued at $115,000 after purchasing an additional 8,839 shares during the period. Oxinas Partners Wealth Management LLC lifted its stake in shares of Global X Genomics & Biotechnology ETF by 12.1% during the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock valued at $137,000 after buying an additional 1,751 shares in the last quarter. Atria Investments Inc boosted its holdings in Global X Genomics & Biotechnology ETF by 12.6% in the 2nd quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after buying an additional 2,073 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after buying an additional 4,615 shares during the period. 56.95% of the stock is currently owned by institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.